Algorhythm Holdings Announces Changes to Board of Directors
September 10, 2024 07:00 ET
|
Algorhythm Holdings, Inc.
Executive Chairman and Two Other Directors Voluntarily Resign Fort Lauderdale, FL, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Algorhythm Holdings, Inc. (“Algorhythm”) (NASDAQ: RIME) – an AI...
Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women
September 10, 2024 07:00 ET
|
Iterum Therapeutics PLC
FDA Decision Expected by PDUFA Goal Date of October 25, 2024 Potential to be First Oral Penem Approved in the U.S. DUBLIN and CHICAGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc...
Beamr Brings Live Streaming to the Next Level With NVIDIA Holoscan for Media
September 10, 2024 07:00 ET
|
Beamr Imaging Ltd.
Beamr will Demonstrate 4K Live Optimization on NVIDIA Holoscan for Media at IBC 2024 in Amsterdam, the Netherlands, from September 13-16, 2024 Herzliya, Israel, Sept. 10, 2024 (GLOBE...
Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
September 10, 2024 07:00 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...
OKYO Pharma Announces Chairman Acquires Shares
September 10, 2024 07:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory Medicine
September 10, 2024 07:00 ET
|
BeyondSpring, Inc.
- Statistically Significant and Clinically Meaningful Efficacy Data with Favorable Benefit/Risk ratio from DUBLIN-3 Phase 3 Study of Plinabulin plus Docetaxel vs. Docetaxel in EGFR Wild-Type NSCLC...
Bitfarms Enhances Operations Teams
September 10, 2024 07:00 ET
|
Bitfarms Ltd.
-Appoints Alex Brammer to Senior Vice President of Global Mining Operations- -Promotes Benoit Gobeil to Chief Infrastructure Officer- -Separates Mining Operations into two divisions, Infrastructure...
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
September 10, 2024 07:00 ET
|
C4 Therapeutics, Inc.
Milestone Results in $8 Million Payment to C4 Therapeutics WATERTOWN, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical...
Cibus Completes First Field Trials in UK for Pod Shatter Reduction in Winter Oilseed Rape
September 10, 2024 07:00 ET
|
Cibus US LLC
Initial data from Pod Shatter Reduction field trials show promising results The first gene edited trait to complete field trials in oilseed rape in the UK SAN DIEGO, Sept. 10, 2024 (GLOBE...
TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization
September 10, 2024 07:00 ET
|
TFF Pharmaceuticals, Inc.
TFF-dry powder HA antigen vaccine candidates induced neutralizing antibody titers in ferrets against H1 and H3 influenza strains Ongoing funded work to assess additional influenza strains FORT...